No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 12
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:38:14.425Z. Latest historical point 2024-03-26. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Kyverna Therapeutics, Inc. (KYTX) stock was $6.21 as of Oct 6, 2026, 10:35 AM EDT, down 1.82% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +14.4%
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis.
Biotechnology · Emeryville, CA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.68
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.63
vs Estimate
$-0.68
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1KYTX | $377.23M | $6.21 | -1.82% | +14.42% | N/A | N/A | N/A |
| 2ARCT | $379.73M | $13.36 | -8.87% | -34.88% | -18.73% | -2.54% | vs KYTX |
| 3MPLT | $380.23M | $8.96 | -3.40% | N/A | N/A | N/A | vs KYTX |
| 4CGC | $370.48M | $0.88 | -0.78% | -35.30% | -63.36% | -31.35% | vs KYTX |
| 5FENC | $354.67M | $10.21 | -3.86% | +7.45% | +2.45% | N/A | vs KYTX |
| 6EMBC | $351.97M | $5.93 | +0.90% | -57.42% | N/A | N/A | vs KYTX |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 5 analysts
Average Price Target
$30.40
+389.9% upside
Low
$25.00
Current
$6.21
High
$33.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.71 | $-0.69 | $-0.66 | 4 |
| Quarter ending Dec 2026 | $-0.83 | $-0.78 | $-0.73 | 4 |
| Quarter ending Mar 2027 | $-0.80 | $-0.80 | $-0.80 | 1 |
| Quarter ending Jun 2027 | $-0.72 | $-0.72 | $-0.72 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.82 | $-2.76 | $-2.68 | 5 |
| FY 2027 | $-3.62 | $-3.12 | $-2.86 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $1.00M | $1.00M | $1.00M | 1 |
| Quarter ending Jun 2027 | $2.03M | $2.03M | $2.03M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $5.54M | $12.50M | $25.93M | 5 |
| FY 2027 | $6.35M | $17.20M | $32.16M | 5 |
